During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that shape access to cellular therapy in early relapsed multiple myeloma.
|Videos|August 7, 2017
Multiple Myeloma With Symptomatic Progression: Case 2
Multiple Myeloma With Symptomatic Progression
Advertisement
Multiple Myeloma With High-Risk Features
July 2017
- A 54-year-old Caucasian male presented to his physician with anemia
- Bone marrow biopsy showed 43% plasma cells
- FISH t(11:14), deletion 13, deletion 17p
- Diagnosis: multiple myeloma with high-risk features
- The patient was treated with lenalidomide, bortezomib, and dexamethasone (VRD) followed by autologous stem cell transplant, and bortezomib maintenance
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Targeted Onc
1
Temab-A Shows Promising Survival in Pretreated Nonsquamous NSCLC
2
Referral Before Salvage Therapy Keeps CAR T an Option in Myeloma
3
FDA Grants RMAT and Fast Track Status to Prizlon-Cel in R/R LBCL
4
DeLLphi-305 Sets a New Standard, and the Bar Is Rising in SCLC
5